Method for the detection of a binding partner of a multispecific binder

Patent metadata

Field	Value
Publication number	US-10761097-B2
Application number	US-201815923773-A
Country	US
Kind code	B2
Filing date	Mar 16, 2018
Priority date	Feb 1, 2012
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

Herein is reported a method for the detection of free antigen of a multispecific antibody in a sample, whereby the antigen to be detected can be specifically bound by a first binding site of the multispecific antibody, comprising the step of incubating a sample comprising free antigen and multispecific antibody with an anti-idiotypic antibody, which specifically binds to a second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase.

First claim

The invention claimed is:

1. A method of determining the amount of free antigen of a bispecific antibody in a sample comprising the bispecific antibody-bound antigen and the free antigen of t h e bispecific antibody, wherein the antigen can be specifically bound by a first binding specificity of the bispecific antibody, comprising the steps of:
(A) incubating a first aliquot of the sample with an additional amount of the bispecific antibody wherein at least 90% of the antigen is complexed by the bispecific antibody in the first aliquot;
(B) incubating the first aliquot of the sample from (A) with an anti-idiotypic antibody, which specifically binds to the second binding specificity of the bispecific antibody, which is different from the first binding specificity of the bispecific antibody, whereby the anti-idiotypic antibody is bound to a solid phase to form a complex comprising the anti-idiotypic antibody, the bispecific antibody, and the antigen;
(C) incubating the complex formed in (B) with an antibody that specifically binds to the antigen at an epitope different from the epitope bound by the bispecific antibody and thereby determining the total amount of the antigen present in the sample from the first aliquot;
(D) incubating a second aliquot of the sample with an anti-idiotypic antibody, which specifically binds to the second binding specificity of the bispecific antibody, which is different from the first binding specificity, whereby the anti-idiotypic antibody is bound to a solid phase to form a complex comprising the anti-idiotypic antibody, the bispecific antibody, and the antigen;
(E) incubating the complex formed in (D) with the antibody that specifically binds to the antigen at an epitope different from the epitope bound by the bispecific antibody and thereby determining the amount antibody-bound antigen of the bispecific antibody present in the sample from the second aliquot; and
(F) determining the amount of free antigen of the bispecific antibody by the difference between the total amount of the antigen present in the sample and the amount of antibody-bound antigen present in the sample.

2. The method according to claim 1 , wherein the amount of the bispecific antibody is between 1 μg/ml and 10 μg/ml in the sample.

3. The method according to claim 1 , wherein at least 95% of the antigen is complexed by the bispecific antibody in the first aliquot.

4. The method according to claim 1 , wherein at least 98% of the antigen is complexed by the bispecific antibody in the first aliquot.

5. The method according to claim 1 , wherein the sample is a blood, plasma, or serum sample.

6. The method according to claim 1 , wherein the bispecific antibody binds to ANG2 and VEGF.

Assignees

• Hoffmann La Roche

Inventors

• Stubenrauch Kay-Gunnar
• Wessels Uwe

Classifications

• G01N33/54306 Primary

  Solid-phase reaction mechanisms · CPC title

• G01N33/543 Primary

  with an insoluble carrier for immobilising immunochemicals · CPC title

• G01N33/6854 Primary

  Immunoglobulins · CPC title

• G01N2333/00

  Assays involving biological materials from specific organisms or of a specific nature · CPC title